Teva Pharmaceuticals has announced new real-world data showing that AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR (extended-release) tablets led to meaningful improvements for adults living with ...
In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by tardive dyskinesia (TD) while taking AUSTEDO or AUSTEDO ...
Teva Pharmaceuticals has a new game plan for raising awareness of tardive dyskinesia (TD). Playing on the chronic movement disorder’s initialism, the pharma has recruited Pro Football Hall of Famer ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has confirmed its initial recommendation to not consider deutetrabenazine as a new active substance. In June this ...
The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from ...
Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR ® (deutetrabenazine) extended-release tablets Patients reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback